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Abstract
Background: The weekly chemoprophylaxis of malaria during pregnancy with chloroquine (CQ)
has become problematic with the increasing resistance of Plasmodium falciparum to this drug. There
was a need to test the benefits of new strategies over the classical chemoprophylaxis. This study
was conducted to provide data to the National Malarial Control Programme for an evidence-based
policy change decision making process. It compares the efficacy of two IPT regimens, using
chloroquine (CQ) or sulphadoxine/pyrimethamine (SP), with the classical chemoprophylaxis
regimen using CQ in reducing the adverse outcomes of malaria infection, for the mother and the
foetus.
Methods: Pregnant women attending the first antenatal care visit were randomly assigned to one
of the three treatment regimens. They were subsequently followed up till delivery. Maternal,
placental and cord blood samples were obtained upon delivery to check for P. falciparum infection.
Results: A total of 648 pregnant women were enrolled in the study. Delivery outcome were
available for 423 of them. Peripheral maternal P. falciparum infection at delivery was found in 25.8%
of the women. The proportion of women with maternal infection was significantly lower in the
IPTp/SP group than in the CQ group (P << 0.000). The prevalence of placental malaria was 18.8%
in the CWC/CQ group; 15.9% in the IPTp/CQ group and 10.6% in the IPTp/SP group. The
incidence of LBW (weigth < 2,500 g) was significantly higher among infants of mothers in the CWC/
CQ group (23.9%) as compared with those of mothers in the IPTp/CQ (15.6%) and IPTp/SP (11.6%)
groups (p = 0.02)
Conclusion: Intermittent preventive treatment with SP has shown clear superiority in reducing
adverse outcomes at delivery, as compared with intermittent preventive treatment with CQ and
classical chemoprophylaxis with CQ.
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Background
In malaria endemic countries, pregnant women, along
with children under five years, represent the most vulner-
able group to Plasmodium falciparum infection [1,2]. Such
infection often increases the risk of morbidity and mortal-
ity for the mother and her child. Indeed, in malaria stable
transmission conditions, it has been shown that preg-
nancy associated with malaria increases the risk of mater-
nal anaemia, stillbirths and low birth weight (LBW) [3,4].
Over 26% of anaemia in pregnancy is attributable to
malaria, and malaria-related maternal deaths are reaching
an unacceptable rate of 23%[5]. These adverse outcomes
have been described as the consequences of placental
sequestration of P. falciparum. In addition, because of this
sequestration, peripheral blood film microscopy usually
underestimates the prevalence of placental malaria [6,7].
In areas of high or moderate transmission, most malaria
infections in pregnant women are asymptomatic and
therefore will not be presented to any clinic for diagnosis
and management. It is important that in such conditions,
strategies to protect mothers during their pregnancy
include the use of insecticide-treated material (ITM) as
well as effective anti-malarial drugs used in intermittent
preventive treatment (IPT) regimens and case manage-
ment [8-10].
In Burkina Faso, until recently, chloroquine (CQ) was the
only drug recommended by the National Malaria Control
Programme for use in chemoprophylaxis against malaria
in pregnant women. However, with the increasing resist-
ance of P. falciparum to chloroquine and the evidence of
the efficacy of IPT in pregnant women using sulphadox-
ine-pyrimethamine (SP), new guidelines were issued in
February 2005 for a policy change regarding the preven-
tion of malaria during pregnancy.
The aim of the present study was to provide data to the
National Malarial Control Programme for an evidence-
based policy change decision making process. The study
has assessed the efficacy of three possible approaches
being considered at the time of the study initiation. It
compares the efficacy of two IPT regimens (using CQ or
SP) with the classical chemoprophylaxis regimen using
CQ in reducing the adverse outcomes of malaria infection
for the mother and the foetus.
Methods
Study site and population
Details on the study site and methods were published by
Ouedraogo et al [11]. Briefly, the study was conducted in
the Antenatal Care Unit of the Health District of Bousse, a
district located around 50 km north-west of Ouaga-
dougou, the capital of Burkina Faso. The district covers a
total population of 124,285 inhabitants. The majority of
this population is farmers, illiterate, and belongs to the
Mossi ethnic group.
The health district is situated within the Mossi Central Pla-
teau, in the Sudano-Sahelian zone, with a tropical climate
characterized by two seasons: the dry season (November -
May), in which malaria transmission is very low, and the
rainy season (June - October), in which malaria transmis-
sion is high. The annual rainfall is in the range of 600 to
900 mm. The main malaria vectors are Anopheles gambiae,
Anopheles arabiensis and Anopheles funestus. Two chromo-
somal forms each of An. gambiae and An. funestus are sym-
patric in the study area. The annual entomological
inoculation rates range from 10 to 500 infective bites per
individual. Plasmodium falciparum is responsible for more
than 90% of malaria infections.
In terms of infrastructure, the Health District includes the
District Hospital, which serves as referral center for 11
community health clinics named Centre de Santé et de
Promotion Sociale (CSPS). The district hospital comprises
a medical unit, a surgery unit and the Child and Maternal
Health Unit (CMHU). Antenatal care and family planning
services are offered by the CMHU. Therefore, the study
staff recruiting team was based there to screen and enrol
women seeking antenatal care who fulfilled the study
inclusion criteria. Among other criteria, eligible women
were required to be permanent residents of the Health
District area with a gestational age between 15 and 36
weeks at the time of the visit, and to have provided freely
given written informed consent. All women who were
otherwise eligible but who had a history of allergic reac-
tion to any of the study drugs (CQ and SP) were excluded.
Selection, randomization and treatment of the study 
participants
In Burkina, three antenatal care unit visits are recom-
mended during pregnancy. The initial visit (ANC1) is
scheduled between the 15th and 25th week of gestational
age; the second visit (ANC2) is scheduled between the 28th
and 32nd week of gestational age, and the third visit
(ANC3) is scheduled between the 33rd and the 36th week
of gestational age.
Pregnant women undergoing their ANC1 who were will-
ing to participate in the study were assessed with regard to
the inclusion and exclusion criteria. Eligible women were
randomly assigned to one of the three treatment arms
using a computer generated random list.
The study pharmacist, who did not take part in any other
activities in the study, prepared an individual randomiza-
tion code envelope from the randomization list. The
sealed envelopes were sequentially numbered. When an
eligible woman joined the study, the envelope with theMalaria Journal 2009, 8:224 http://www.malariajournal.com/content/8/1/224
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lowest available number was opened, revealing the
assignment of the participant to the appropriate treatment
arm.
The first treatment arm was classical weekly chemoproph-
ylaxis using chloroquine (CWC/CQ). Participants in this
arm received, upon enrolment, a curative dose of CQ (600
mg/day at Day 0, then 300 mg/day at Day 1 and Day 2)
followed by 300 mg/week until 6 weeks post delivery. The
second and third treatment arms consisted of intermittent
preventive treatment in pregnancy (IPTp) regimens. For
the second arm (IPTp/CQ), the IPTp regimen was a com-
plete cure with CQ at each of the antenatal care visits
(ANC1, ANC2 and ANC3). A total dose of 600 mg/day of
CQ was administered at Day 0, then 300 mg/day at Day 1
and Day 2. In the third arm (IPTp/SP), the IPTp regimen
consisted of a single curative dose of 1.5 g/0.075 g sul-
phadoxine pyrimethamine at each of the antenatal care
visits (ANC1, ANC2 and ANC3). The treatment administra-
tion was not supervised. Each woman was given medica-
tion, according to her treatment arm, for self-
administration after leaving the clinic.
Follow-up of the study participants
Enrolled pregnant women were followed up to delivery.
At enrolment and subsequent visits, the study midwife
collected the study data using a standardized question-
naire. During the pregnancy, the following data were col-
lected: sociodemographic factors (age, village, school
attendance, marital status), obstetrical past history (gra-
vidity, parity), pregnancy related factors (number of ANC
visits, oedema, malaria episode), and malaria prevention
measures (chemoprophylaxis and use of bed nets). A
physical examination was performed to measure axillary
temperature, blood pressure, weight and uterine height.
A blood sample was obtained by fingerprick for a blood
smear and haemoglobin (Hb) was measured using a port-
able hemocue (HemoCue® AB, Ängelholm, Sweden). Anae-
mia was defined as Hb < 11 g/dL. An Hb level between 8
and 11 g/dL was considered mild to moderate anemia and
an Hb level ≤ 8 g/dL as severe anaemia.
In participants diagnosed with fever (axillary T° ≥
37.5°C), a malaria rapid diagnosis test (OPTimal®) was
done to allow prompt management of the case. Results of
the impact of the three treatment arms in terms of mater-
nal infection and prevalence of maternal anaemia have
been published elsewhere by Ouedraogo et al [11]
At delivery, data regarding newborn characteristics (vital
status at birth, birth weight, sex and the presence of twins
or malformation) were collected. Birth weight was meas-
ured using an electronic digital scale (± 10 grams) (Tanita
Corporation, Tokyo, Japan). In addition, cord blood sam-
ples were obtained for smears and placental blood smears
were obtained from the maternal side of the placenta. A
malaria smear was also obtained from the mother by fin-
gerprick. No sample was obtained from the neonate to
check for malaria parasites.
Management of anaemia and malaria cases
Study participants found to be anaemic at ANC visits (Hb
level < 11 g/dL) were treated, based on national guide-
lines, with ferrous sulfate (200 mg) and folic acid (0.25
mg) given as a single combined tablet daily for 30 days.
Confirmed cases of malaria (axillary T° ≥ 37.5°C and
with a positive rapid diagnosis test) were given treatment
with quinine, based on the national malaria treatment
guidelines for pregnant women.
Laboratory methods
All blood films (maternal, placental and cord) were
stained with 10% Giemsa for 45 min, and read at the Cen-
tre National de Recherche et de Formation sur le Palud-
isme (CNRFP) immunoparasitology laboratory in
Ouagadougou. For thick films, parasites and leukocytes
were counted in the same fields until 500 leukocytes were
counted. Parasite densities were estimated using an
assumed leukocyte count of 8,000 leukocytes/μL. Thin
films were then used to determine species when thick
films were positive. All slides were double read by two
independent microscopists. If the ratio of densities from
the first two readings were > 1.5 or < 0.67 or if < 30 para-
sites were counted with a difference in the number of par-
asites > 10, the slide was evaluated a third time. The final
result was the geometric mean of the parasite density of
the two most concordant results of the three readings.
When the discordance was only in terms of positivity, the
slide was also evaluated a third time and the definitive
result was based on the majority verdict for positivity. Pla-
cental histology was not performed.
Statistical analysis
The data collected in the study questionnaire were verified
then double entered using Epi-info 6.04 fr (CDC, Atlanta,
USA). Data were analysed using Epi-info and Sata 7.0.
Analysis was by intent-to-treat. The analysis included data
from births of all enrolled participants who had taken the
study treatment at least once and who delivered at the
study centre clinic for which data are available. Continu-
ous normally distributed data were described by the mean
and standard deviation, and non-normally distributed
data by the median or geometrical mean and range.
Proportions were compared using the Chi square test and
normally distributed continuous variables were compared
using Student's t test. Statistical tests were considered sig-
nificant when the two-sided P value was < 0.05.Malaria Journal 2009, 8:224 http://www.malariajournal.com/content/8/1/224
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Ethical considerations
The study was initially discussed with health authorities
and local leaders to obtain their assent. The study was sub-
mitted to and approved by the National Ethical Review
Committee in Burkina Faso and the Ethical Committee of
WHO/TDR. A written informed consent was obtained
from all the women prior to their enrolment in the study.
For illiterate mothers, the informed consent discussion
process was witnessed by an impartial individual.
Results
Characteristics of the study participants at enrolment
The trial profile is provided in Figure 1. In total, 648 preg-
nant women were recruited and randomized to one of the
three study arms. Baseline characteristics were similar
within the study groups (Table 1). The mean age (SD) of
the participants was 23.7 (5.9) and 39.7% of them (257)
were primigravidae. The primigravidae and secundigravi-
dae represent 58.7% of the total sample size. Over half of
the women (50.8%) were parasitaemic at enrolment; this
proportion was significantly higher for women rand-
omized to the IPTp/SP group (p = 0.005). Overall, the
geometric mean of the parasite density was 855.4 (95% ci
691.6-1058.06). There was no difference between treat-
ment groups. The rate of use of insecticide impregnated
materials (bed nets and/or curtains) was very low in the
study population and was comparable across the study
groups.
One woman (0.24%) in the IPTp/SP group died during
the delivery as the consequence of eclampsia. Other com-
plications during the delivery included peripartum haem-
orrhage (1.18%), placental retention (1.9%), and retro-
placental haemorrhage (1.4%). Two stillbirths (0.4%)
were recorded.
Placental malaria and low birth weight
A total of 423 women were followed up until delivery;
they were similarly distributed in the three treatment
groups (see Table 2). Overall, peripheral maternal P. falci-
parum infection at delivery was found in 25.8% of the
women. The proportion of women with maternal infec-
tion was significantly lower in the IPTp/SP group than in
the CQ group (P << 0.000). Among all the delivering
primigravidae, the proportion of women with maternal
infection was almost double in the CWC/CQ group com-
pared with the IPT groups. The difference was statistically
significant (p << 0.000). Among the secundigravidae,
although the highest proportion of infected mothers was
observed in the IPT groups (47.8% for the IPTp/CQ group
and 22.7% for the IPTp/SP group) as compared to the
CWC/CQ group (20.0%), this result did not reach signifi-
cance level (p = 0.07).
The prevalence of placental malaria was 18.8% in the
CWC/CQ group; 15.9% in the IPTp/CQ group and 10.6%
in the IPTp/SP group. These trends remained unchanged
after stratification according to level of gravidity (Table 2).
Statistically significant differences were only found
between the CWC/CQ group and the IPTp/SP group (p =
0.049).
After adjustment, women in the IPTp/SP group had a
lower risk of placental malaria when compared with those
in the CWC/CQ group (OR = 0.44 (95% ci 0.22-0.90), p
= 0.025). No significant difference was observed between
the women in the IPTp/CQ group and those in the CWC/
CQ group (OR = 0.75 (95% ci 0.4-1.41), p = 0.39). The
mean birth weight was 2,802 g (1,100 to 4,100); there
were no differences among the treatment groups in mean
birth weight.
In total, 17.3% of the newborns had a low birth weight
(LBW) (weight < 2,500 g). The incidence of LBW was sig-
nificantly higher among infants of mothers in the CWC/
CQ group (23.9%) as compared with those of mothers in
the IPTp/CQ (15.6%) and IPTp/SP (11.6%) groups (p =
0.02). The use of IPTp either with CQ or SP was associated
with lower risk of LBW; thus, the adjusted risk of LBW was
significantly lower for infants of mothers in the IPTp/SP
group as compared with those from the CWC/CQ group
(OR = 0.38 (95% ci (0.19-0.72), p = 0.004). A similar sit-
uation was observed when comparing infants of mothers
in the IPTp/CQ and those of mothers in the CWC/CQ
group (OR = 0.53, 95% ci (0.29-0.98), p = 0.045).
As presented in Table 2, among primigravidae, the pro-
portion of infants with LBW was significantly higher in
the CWC/CQ group (40.9%, versus 18.9% in IPTp/CQ
and 14.5% in IPTp/SP groups, p = 0.004). In secundigravi-
dae and multigravidae mothers, the proportion of infants
with LBW was also higher in the CWC/CQ group, but this
difference did not reach statistical significance.
Cord blood parasitaemia was found in six cases; four of
them were from the CWC/CQ group, one in the IPTp/CQ
group and one in the IPTp/SP group. The difference was
not statistically significant (p = 0.19).
Discussion
This study compared the efficacy of three treatment regi-
mens for the prevention of placental malaria: classical
chemoprophylaxis using CQ, intermittent preventive
treatment using CQ, and intermittent preventive treat-
ment using two doses of SP.
This study was conducted at the time of a transition
period in Burkina Faso; CWC/CQ was still the regimen
recommended by the National Malaria Control Pro-
gramme for preventing malaria during pregnancy, but the
declining efficacy of CQ had lead to the initiation of dis-
cussion of a change in this policy.Malaria Journal 2009, 8:224 http://www.malariajournal.com/content/8/1/224
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The trial profile Figure 1
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The IPTp/SP regimen was more effective than the other
two regimens in preventing placental malaria. No differ-
ence was found between the IPTp/CQ and the CWC/CQ
regimens. Significant differences were only found
between the CWC/CQ and IPTp/SP groups, suggesting
that, in addition to the high resistance of P. falciparum to
CQ in the area, [12,13] the low efficacy observed with the
CWC/CQ is probably also related to the issue of compli-
ance. Compliance issues with this type of treatment regi-
men have been commonly observed in women living in
settings comparable to those of our study population.
The risk of placental malaria was significantly higher in
the CWC/CQ as compared to the IPTp/SP group. This
finding is consistent with those reported in similar studies
which have shown that IPTp with SP is more efficacious
than chemoprophylaxis with CQ in preventing placental
malaria [14-16].
The IPTp/SP regimen was also more efficacious in reduc-
ing the proportion of LBW as compared with the two
other CQ regimens. These findings are consistent with
what has been reported in similar studies [14,17]. The effi-
cacy of all three-treatment regimens in preventing mater-
nal infection, placental malaria, and low birth weight
increased with gravidity. This finding confirms the high
burden of malaria for women with low gravidity in areas
with intense parasite transmission. Indeed, in high
malaria endemicity settings, primigravidae and, to a lesser
extent, secundigravidae are known to be more highly
affected than other parities [18].
The proportion of premature delivery was unexpectedly
high in all three-treatment regimens. No significant differ-
ences were observed between the groups. Considering the
efficacy of IPTp/SP in preventing placental malaria infec-
tion, and CQ's potential antipyretic effect (mediated by
inhibition of tumour necrosis factor) [19], one may
expect lower premature delivery rates comparable with
those reported in other studies using the same anti-malar-
ial drugs [14,15,20]. It is possible that in this case, the ges-
tational ages were overestimated in some cases due to a
recall bias (of the date of last menstrual period, which is
used to estimate the gestational age at the first antenatal
clinic visit) by the mothers.
Conclusion
From the perspective of reducing the adverse conse-
quences of malaria on pregnancy outcomes, IPTp/SP has
shown clear superiority as compared with IPTp/CQ and
classical chemoprophylaxis with CQ. These results indi-
cate that IPTp/SP treatment could be adopted as the offi-
cial recommended treatment for pregnant women, while
alternative drugs for IPT are being investigated.
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Table 1: Baseline characteristics of the study participants
Characteristics CWC/CQ
n = 209
IPTp/CQ
N = 221
IPTp/SP
n = 218
All participants N = 648 P
Age
(mean ± SD; range)
24.3 ± 6.3 (16; 51) 23.3 ± 5.7 (17; 42) 23.6 ± 5.8 (17; 45) 23.7 ± 5.9 (16; 51) 0.16
Parity
(mean ± SD; range)
1.7 ± 0.01 (0; 8) 1.5 ± 0.01
(0; 9)
1.4 ± 0.01
(0; 7)
1.5 ± 0.01
(0; 9)
0.07
Primigravidae (%) 32.2 42.5 44.0 39.7 0.02
Secundigravidae (%) 21.2 19.0 17.0 19.0 0.56
Multigravidae (%) 46.6 38.5 39.0 41.3 0.18
Weight
(mean ± SD; range)
54.6 ± 6.3 (41, 80) 54.8 ± 8.3 (39; 79) 55.7 ± 8.2 (40;105) 55.2 ± 7.7 (39;105) 0.54
Gestational age
(mean ± SD)
21.8 ± 2.8 21.6 ± 2.8 21.75 ± 2.7 21.75 ± 2.7 0.67
Uterine fundal Height
(mean ± SD; range)
21.4 ± 3.3 (13; 30) 21.2 ± 3.2 (13; 30) 21.2 ± 2.8
(14; 27)
21.3 ± 3.1 (13; 30) 0.66
Parasitaemia (mean, 95% CI) 666.6 (450.9 985.6 908.1
(636.5-1295.8)
951.8
(661.5-1369.4)
855.4 (691.6-1058.06) 0.27
Parasitaemia (%) 41.5% 55.0% 55.3% 50.8% 0.005
Haemoglobin level
(mean ± DS; range)
10.9 ± 1.5 (5.1;15.2) 10.9 ± 1.4 (7.0; 14.0) 10.4 ± 1.3
(7.8; 14.6)
11.0 ± 1.4 (5.1; 15.2) 0.81
Impregnated bed nets (%) 4.3 6.8 5.0 5.4 0.50
Non-impregnated bed nets (%) 9.6 6.3 6.9 7.56 0.39
Impregnated curtains (%) 2.9 2.3 2.3 2.5 0.89
Non-impregnated curtains (%) 56.3 67.0 59.6 61.0 0.06Malaria Journal 2009, 8:224 http://www.malariajournal.com/content/8/1/224
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